WeVote
Log In

Bill

MB

Bill

HR 6220

MIRACLE Act of 2025

119th Congress Introduced by Michael Baumgartner and 2 co-sponsors

Establishes federal medical research innovation framework and regulatory infrastructure with bipartisan support, referred to Energy and Commerce Committee for healthcare policy consideration.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 6220

Legislative bill overview

HR 6220, the MIRACLE Act of 2025, establishes a federal framework for regulating and supporting medical innovation and research infrastructure. The bill, introduced by bipartisan sponsors from Washington state, was referred to the House Committee on Energy and Commerce for consideration. The specific mechanisms and provisions would be detailed in the bill's text, which would outline funding mechanisms, regulatory requirements, or institutional changes related to medical research and development.

Why is this important

Medical research infrastructure and innovation policy directly affect the speed and cost of developing new treatments, drugs, and medical technologies that impact public health outcomes. Federal support for research facilities and regulatory clarity can influence whether promising treatments reach patients efficiently or face lengthy delays. The involvement of the Energy and Commerce Committee suggests this likely addresses healthcare innovation, FDA processes, or research facility standards that have broad implications for the pharmaceutical and biotech industries.

Potential points of contention

  • Funding allocation: Whether federal resources should prioritize certain research areas (rare diseases, common conditions, preventive medicine) and whether funding mechanisms create winners and losers among research institutions
  • Regulatory burden: How new requirements for research facilities or innovation approval processes might accelerate or slow medical breakthroughs, and whether compliance costs disadvantage smaller organizations
  • Industry-government balance: The extent to which private pharmaceutical companies versus public research institutions should drive innovation priorities and profit from federally-supported discoveries

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.